This program aims to develop VEGF × DLL4 therapeutic bispecific antibody for immuno-oncology.
Rationale when developing the program:
DLL4 is a protein-coding gene that acts as a ligand for Notch receptors family. It plays a vital role in normal development and tissue homeostasis in the immune system, gastrointestinal tract and vascular system. Also, because Notch signaling is a very important mechanism in the maintenance and proliferation of cancer stem cells (CSCs), thus, DLL4 also plays an important role in stem cell biology.
VEGF, on the other hand, is a key mediator for angiogenesis in cancer and considered to have potent anti-cancer effects.
MOA of VEGF and DLL4:
Fig.1 VEGF and Dll4 regulate blood vessel branching and expansion.2
VEGF × DLL4 in Cancer Studies
Here are some published data about VEGF × DLL4 work as a potential target for cancer immunotherapy.
Fig.2 MDA-MB-231 tumor growth curves and tumor inhibition rates for nude mice of different dosage groups.1
We have extensive knowledge of end-to-end program development. For each program, we are committed to delivering the final complete program to our clients within 1.5 years before entering the IND stage.
Fig.3 Project pipeline management of therapeutic monoclonal antibody.
Creative Biolabs is looking for potential partners (include but not limit to major pharma or biotech firms) to develop VEGF × DLL4 bispecific antibody program together. Our scientists are dedicated to bringing years of valuable experience to our partner and achieve a meaningful partnership. For any partners interested in our Next-IO™ programs, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from the discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate for our programs.
With our quality control protocol and knowledge of global regulatory requirements, we can help our partners advance their programs with more chance to succeed. Look forward to cooperating with you in the near future.
For Research Use Only | Not For Clinical Use